Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy

Clinical Cancer Research

Volumn 12, Issue 20 PART 1, 2006, Pages 6018-6022

  Reeves, Jonathan R ^a   Dulude, Hélène ^a   Panchal, Chandra ^a   Daigneault, Luc ^a   Ramnani, Dharam M ^b  

^a Ambrilia Biopharma Inc   (Canada)

^b Virginia Urology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA MICROSEMINOPROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GLEASON SCORE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

ALPHA-FETOPROTEINS; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; RECURRENCE; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750731985     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0625     Document Type: Article

References (19)

1. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2005;165:1562-8.
2. Albertson PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
3. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a murticenter clinical trial of 6,630 men. J Urol 1994;151:1283-90.
4. Day JC. Populations projections of the United States by age, sex and Hispanic origin: 1995-2050. U.S. Bureau of Census, Washington, DC, 1996.
5. Lilja H, Abrahamsson PA. Three predominant proteins secreted by the human prostate gland. Prostate 1988;12:29-38.
6. Garde SV, Basrur VS, Li L, et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cell line (PC3) and xenografts by inducing apoptosis. Prostate 1999;38:118-25.
7. Shukeir A, Arakelian A, Kadhim S, Garde S, Rabbani SA. Prostate secretory protein (PSP-94) decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 2003;63:2072-78.
8. Huang C, Brassil D, Rossell M, Schellhammer PF, Wright GL, Jr. Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 1993;23:201-12.
9. Abrahamsson PA, Andersson C, Bjork T, et al. Radioimmunoassay of β-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989;35:1497-503.
10. Teni TR, Sheth AR, Kamath MR, Sheth NA. Serum and urinary prostatic-inhibin-like peptide (PIP) in benign prostatic hyperplasia and carcinoma of the prostate. Cancer Lett 1988;43:9-14.
11. von der Kammer H, Jurincic-Winkler C, Horlbeck R, Klippel KF, Pixberg HU, Scheit KH. The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol Res 1993;21:227-33.
12. Wu D, Guo Y, Chambers AF, Izawa J, Chin J, Xuan JW. Serum bound forms of PSP94 (prostate secretory protein of 94 amino acids) in prostate cancer patients. J Cell Biochem 1999;76:71-83.
13. Bauman G, Xuan JW, Chin J, et al. PSP94: evaluation of prognostic utility in patients treated with radiotherapy for non-metastatic prostate cancer. Prostate J 2000;2:94-101.
14. Reeves JR, Xuan JW, Arfanis K, et al. Identification, purification and characterization of a novel human blood protein with binding affinity for prostate secretory protein of 94 amino acids. Biochem J 2005;385:105-14.
15. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Bioanalytical Method Validation, Guidance for Industry. 2001.
16. Ren C, Li L, Yang G, et al. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. Cancer Res 2003;64:969-76.
17. + channel inhibitor-like fold. J Biol Chem 2005;280:12405-12.
18. Kumar-Sinha C, Chinnaiyan AM. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. Urology 2003;62:19-35.
19. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-53.